AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
PetVivo Holdings, Inc.
Video analysis: PETV
All videosNo video analysis for this stock yet. Request one from our team.
News: PETV
PETVIVO HOLDINGS ANNOUNCES NAME CHANGE OF HUMAN SUBSIDIARY TO SOMATRIX TECHNOLOGIES, INC. AND EXPANDS FOCUS ON HUMAN HEALTH INNOVATION
New Human Health Subsidiary to Advance Development of Innovative Biomaterial Technologies and Potential New Products for Human and Animal Health MINNEAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV) ("PetVivo" or the "Company"), an emerging biomedical device company focused on the commercialization and development of innovative medical devices and therapeutics, announced today that its subsidiary, Cosmeta Corp.
PetVivo Holdings, Inc. (PETV) Q1 2027 Earnings Call Transcript
PetVivo Holdings, Inc. (PETV) Q1 2027 Earnings Call Transcript
PetVivo, a Leading Provider of Veterinary Biomedicals, Reports Results for Fiscal Q1 2027
MINNEAPOLIS, MN, US, Aug. 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV), in cooperation with its wholly owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported financial and operational results for the first quarter of its fiscal year ended June 30, 2026.
PetVivo Sets Fiscal First Quarter 2027 Conference Call for Friday, August 14, 2026 at 5:00 p.m. ET
MINNEAPOLIS, MN, US, Aug. 07, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), an emerging biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Friday, August 14, 2026 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2026.
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
Agreement Resolves All Outstanding Matters and Completes Transition of PrecisePRP ® Product Line MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc. (collectively "PetVivo" or the “Company”), an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for horses and companion animals, today announced that it has entered into a Termination and Settlement Agreement with VetStem, Inc., effective July 24, 2026. Under the agreement, the parties have terminated their Exclusive License and Supply Agreement relating to the PrecisePRP® product line, resolved all matters arising under the parties' prior Exclusive License and Supply Agreement, and established an orderly transition of the remaining PrecisePRP® inventory and related commercial activities.
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
Agreement Resolves All Outstanding Matters and Completes Transition of PrecisePRP Product Line MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) working in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. , Cosmeta Corp and PetVivo AI, Inc.
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minneapolis, MN, July 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced the publication of a peer-reviewed clinical study evaluating Spryng® with OsteoCushion® Technology in the peer-reviewed journal Veterinary Record. The publication represents another important milestone in the continued expansion of the scientific evidence supporting Spryng® with OsteoCushion® Technology and reflects the growing interest among veterinary orthopedic specialists in evaluating novel biomaterial technologies for the management of canine osteoarthritis and cranial cruciate ligament disease.
PetVivo Holdings, Inc. (PETV) Q4 2026 Earnings Call Prepared Remarks Transcript
PetVivo Holdings, Inc. (PETV) Q4 2026 Earnings Call Prepared Remarks Transcript
